Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, Non-Hodgkin

Explore clinical trials studying Lymphoma, Non-Hodgkin. Study availability and eligibility vary by location and protocol.

229 public trials 24 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, Non-Hodgkin trial results

Enrolling by invitation

Long-Term Follow-up Study

NCT05332054

Conditions
B Cell Lymphoma, B-cell Non-Hodgkin's Lymphoma, Blood Protein Disorders, +29 more
Locations
  • University of Alabama Birmingham, Alabama, United States
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Honor Health Research Institute Scottsdale, Arizona, United States
  • University of California Irvine Irvine, California, United States
View all 31 locations
View Trial Details
Active, not recruiting

A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

NCT06470438

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Beijing Cancer Hospital Beijing, China
  • Sun Yat Sen University Cancer Center Guangzhou, China
  • The First Affiliated Hospital Zhejiang University College of Medicine Hangzhou, China
  • Fudan University Shanghai Cancer Center Shanghai, China
View all 19 locations
View Trial Details
Active, not recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

NCT06139406

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Austin Hospital Heidelberg, Australia
  • The Alfred Hospital Melbourne, Australia
  • Linear Clinical Research Ltd Nedlands, Australia
  • Scientia Clinical Research Randwick, Australia
View Trial Details
Active, not recruiting

A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL)

NCT06660563

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • Concord Hospital Concord, Australia
  • St Vincents Hospital Melbourne Fitzroy, Australia
  • Macquarie University Hospital North Ryde, Australia
  • Hosp Univ Vall D Hebron Barcelona, Spain
View Trial Details
Active, not recruiting

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

NCT05421663

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • City of Hope Duarte, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • University of Iowa Hospital and Clinics Iowa City, Iowa, United States
  • University of Kentucky Medical Center Lexington, Kentucky, United States
View all 32 locations
View Trial Details
Active, not recruiting

A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

NCT05424822

Conditions
Chronic Disease, Disease Attributes, Hematologic Diseases, +15 more
Locations
  • City of Hope Duarte, California, United States
  • Icahn School of Medicine at Mount Sinai New York, United States
  • Memorial Sloan Kettering Cancer Center New York, United States
  • Sarah Cannon Research Institute Nashville, Tennessee, United States
View all 29 locations
View Trial Details
Active, not recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT04077723

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +6 more
Locations
  • City of Hope Medical Center Pasadena, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • The University of Texas MD Anderson Cancer Center Houston, Texas, United States
View all 35 locations
View Trial Details
Active, not recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

NCT05020678

Conditions
Aggressive Lymphoma, B-cell Acute Lymphoblastic Leukemia, Blood Protein Disorders, +43 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • The Cleveland Clinic Foundation Cleveland, Ohio, United States
  • Institute of Haematology, Royal Prince Alfred Hospital Camperdown, New South Wales, Australia
  • St. Vincent's Hospital Sydney, New South Wales, Australia
View Trial Details

Related conditions